[{"id":"88f3eaef-14f2-44c3-90f7-c4ebafee84e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474064","created_at":"2026-03-28T01:40:03.816Z","updated_at":"2026-03-28T01:40:03.816Z","phase":"Phase 2","brief_title":"Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC","source_id_and_acronym":"NCT07474064","lead_sponsor":"chenxu","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 03/26/2026","start_date":" 03/26/2026","primary_txt":" Primary completion: 03/31/2031","primary_completion_date":" 03/31/2031","study_txt":" Completion: 03/31/2035","study_completion_date":" 03/31/2035","last_update_posted":"2026-03-17"},{"id":"7152824f-51d6-434a-a17c-b34a21be5fde","acronym":"","url":"https://clinicaltrials.gov/study/NCT07037004","created_at":"2025-06-28T13:42:45.741Z","updated_at":"2025-06-28T13:42:45.741Z","phase":"Phase 2","brief_title":"Adding a Probiotic (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery","source_id_and_acronym":"NCT07037004","lead_sponsor":"City of Hope Medical Center","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 05/04/2026","start_date":" 05/04/2026","primary_txt":" Primary completion: 05/04/2027","primary_completion_date":" 05/04/2027","study_txt":" Completion: 05/04/2027","study_completion_date":" 05/04/2027","last_update_posted":"2025-06-25"},{"id":"06ab7f9b-1285-4ff7-8e07-6a4608ecb3c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922035","created_at":"2024-02-22T20:26:04.668Z","updated_at":"2024-07-02T16:35:18.238Z","phase":"Phase 1","brief_title":"CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant","source_id_and_acronym":"NCT03922035","lead_sponsor":"City of Hope Medical Center","biomarkers":" TNFA • TNFRSF1A • TGFB1","pipe":"","alterations":" ","tags":["TNFA • TNFRSF1A • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cdactin-O (CBM588)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/18/2019","start_date":" 04/18/2019","primary_txt":" Primary completion: 12/24/2024","primary_completion_date":" 12/24/2024","study_txt":" Completion: 12/24/2024","study_completion_date":" 12/24/2024","last_update_posted":"2024-02-22"},{"id":"b12338e0-fa45-447b-8e22-dd27c2e163c2","acronym":"P30CA033572","url":"https://clinicaltrials.gov/study/NCT03829111","created_at":"2024-01-02T17:17:16.914Z","updated_at":"2024-07-02T16:35:24.804Z","phase":"Phase 1","brief_title":"CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer","source_id_and_acronym":"NCT03829111 - P30CA033572","lead_sponsor":"City of Hope Medical Center","biomarkers":" IL6 • CXCL8","pipe":"","alterations":" ","tags":["IL6 • CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cdactin-O (CBM588)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/14/2019","start_date":" 05/14/2019","primary_txt":" Primary completion: 06/11/2024","primary_completion_date":" 06/11/2024","study_txt":" Completion: 06/11/2024","study_completion_date":" 06/11/2024","last_update_posted":"2024-01-01"}]